Anzeige
Mehr »
Login
Samstag, 07.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QAB | ISIN: US92829J2033 | Ticker-Symbol:
NASDAQ
06.12.24
20:22 Uhr
2,410 US-Dollar
+0,150
+6,64 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DOGWOOD THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DOGWOOD THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DOGWOOD THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.11.Dogwood Therapeutics, Inc. - 8-K, Current Report-
18.11.DWTX-Aktie erreicht 52-Wochen-Tief bei 2,5 US-Dollar1
18.11.DWTX stock touches 52-week low at $2.5 amid market challenges1
18.11.Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study80- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo...
► Artikel lesen
08.11.Dogwood Therapeutics, Inc. - 10-Q, Quarterly Report3
07.11.Dogwood Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary1
07.11.Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Third Quarter 2024 Financial Results62- Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the "Combination")...
► Artikel lesen
07.11.Dogwood Therapeutics, Inc. - 8-K, Current Report-
DOGWOOD THERAPEUTICS Aktie jetzt für 0€ handeln
31.10.Dogwood Therapeutics, Inc.: Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 20241
30.10.Dogwood Therapeutics regains compliance with Nasdaq's minimum bid price rule2
30.10.Dogwood Therapeutics regains Nasdaq compliance1
30.10.Dogwood Therapeutics, Inc. - 8-K, Current Report1
30.10.Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement133ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), formerly Virios Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today...
► Artikel lesen
08.10.Kursziel für Virios Therapeutics nach Fusion mit Wex angehoben5
07.10.Virios Therapeutics, Inc. - 8-K, Current Report3
07.10.Virios Therapeutics, Wex Pharmaceuticals To Combine1
07.10.Virios Therapeutics, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics3
07.10.Virios Therapeutics announces strategic merger and financing4
07.10.Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX")275Strategic financing by an affiliate of CK Life Sciences Int'l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development...
► Artikel lesen
01.10.Virios Therapeutics stock hits 52-week low at $0.151
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1